Login to Your Account

Other News To Note

Monday, August 19, 2013
Cadence Pharmaceuticals Inc., of San Diego, said the U.S. Patent and Trademark Office (USPTO) has issued a non-final, initial office action in the ex parte reexamination of U.S. Patent No. 6,028,222, or the '222 patent, one of the two licensed patents covering Ofirmev (acetaminophen) injection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription